Journal of Infection
Volume 51, Issue 5 , Pages e261-e264 , December 2005

Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B

,Accepted 22 March 2005.

References 

  1. Del Giudice P, Marty P, Lacour JP, Perrin C, Pratlong F, Haas H, et al. Cutaneous leishmaniasis due to Leishmania infantum. Case reports and literature review. Arch Dermatol. 1998;134(2):684–703
  2. Grevelink SA, Lerner EA. Leishmaniasis. J Am Acad Dermatol. 1996;34:257–272
  3. Mahboudi F, Abholhassani M, Tehrani SE, Azimi M, Asmar M. Differentiation of old and new world Leishmania species at complex and species levels by PCR. Scand J Infect Dis. 2002;34:756–758
  4. Etges R, Müller I. Progressive disease or protective immunity to Leishmania major infection: the result of a network of stimulatory and inhibitory interactions. J Mol Med. 1998;76(6):372–390
  5. Guerbouj S, Guizani I, Speybroeck N, Le Ray D, Dujardin JC. Genomic polymorphism of Leishmania infantum: a relationship with clinical pleomorphism?. Infect Genet Evol. 2001;1(1):49–59
  6. Walsh DS, Balagon MV, Abalos RM, Tiongco ES, Cellona RV, Fajardo TT, et al. Multiple lesions of sporotrichoid leishmaniasis in a Filipino expatriate. J Am Acad Dermatol. 1997;36(55 Pt 2):847–849
  7. Choi CM, Lerner EA. Leishmaniasis: recognition and management with a focus on immunocompromised patient. Am J Clin Dermatol. 2002;3(2):91–105
  8. Didona B, Gobello T, Vittucci V, Bergamo F, Cavalieri R. Leishmaniosi cutanea a noduli multipli disseminati. Chron Derm. 1988;87(1):133–138
  9. Marovich MA, Lira R, Shepard M, Fuchs GH, Kruetzer R, Nutman TB, et al. Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment. Clin Infect Dis. 2001;33(1):1076–1079
  10. Martin Sanchez J, Pineda JA, Andreu-Lopez M, Delgado J, Macias J, De La Rosa R, et al. The high sensitivity of a PCR-ELISA in the diagnosis of cutaneous and visceral leishmaniasis caused by Leishmania infantum. Ann Trop Med Parasitol. 2002;96(7):669–677
  11. Croft SL, Yardley V. Management of cutaneous leishmaniasis. Curr Pharm Des. 2002;8(4):319–342
  12. Hepburn NC. Cutaneous leishmaniasis: current and future management. Expert Rev Anti Infect Ther. 2003;1(4):563–570
  13. Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis. 2002;15(6):593–598
  14. Rapp C, Imbert P, Darie H, Simon F, Gros P, Debord T, et al. Liposomal amphotericin B treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniate. Bull Soc Pathol Exot. 2003;96(3):209–211
  15. Amato VS, Rabello A, Rotondo-Silva A, Kono A, Maldonado TP, Alves IC, et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop. 2004;92(2):127–132

PII: S0163-4453(05)00100-3

doi: 10.1016/j.jinf.2005.03.012

Journal of Infection
Volume 51, Issue 5 , Pages e261-e264 , December 2005

Article Tools

* Image Usage & Resolution